The global Anti-erectile Dysfunction (ED) Drugs market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers:
This report presents an overview of global market for Anti-erectile Dysfunction (ED) Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Anti-erectile Dysfunction (ED) Drugs, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Anti-erectile Dysfunction (ED) Drugs, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Anti-erectile Dysfunction (ED) Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Anti-erectile Dysfunction (ED) Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type, and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Anti-erectile Dysfunction (ED) Drugs sales, projected growth trends, production technology, application and end-user industry.
麻豆原创 Segmentation
By Company
Pfizer
Bayer
Hims
Menarini Group
Lupin
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
General Factory
CSBio
Dong-A ST
Metuchen Pharma
Seoul Pharma
Teva Pharma
S.K. Chemicals
Segment by Type
Sildenafil (Viagra)
Vardenafil (Levitra, Staxyn)
Tadalafil (Cialis)
Avanafil (Stendra)
Udenafil (Zydena)
Others
Segment by Application
Hospital
Retail Pharmacy
Clinic
Online Pharmacy
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Anti-erectile Dysfunction (ED) Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Anti-erectile Dysfunction (ED) Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, sales, and revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: China by Type, and by Application, sales, and revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, sales, and revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Anti-erectile Dysfunction (ED) Drugs sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Study Coverage
1.1 Anti-erectile Dysfunction (ED) Drugs Product Introduction
1.2 麻豆原创 by Type
1.2.1 Global Anti-erectile Dysfunction (ED) Drugs 麻豆原创 Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Sildenafil (Viagra)
1.2.3 Vardenafil (Levitra, Staxyn)
1.2.4 Tadalafil (Cialis)
1.2.5 Avanafil (Stendra)
1.2.6 Udenafil (Zydena)
1.2.7 Others
1.3 麻豆原创 by Application
1.3.1 Global Anti-erectile Dysfunction (ED) Drugs 麻豆原创 Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Clinic
1.3.5 Online Pharmacy
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Anti-erectile Dysfunction (ED) Drugs Sales Estimates and Forecasts 2019-2030
2.2 Global Anti-erectile Dysfunction (ED) Drugs Revenue by Region
2.2.1 Global Anti-erectile Dysfunction (ED) Drugs Revenue by Region: 2019 VS 2023 VS 2030
2.2.2 Global Anti-erectile Dysfunction (ED) Drugs Revenue by Region (2019-2024)
2.2.3 Global Anti-erectile Dysfunction (ED) Drugs Revenue by Region (2025-2030)
2.2.4 Global Anti-erectile Dysfunction (ED) Drugs Revenue 麻豆原创 Share by Region (2019-2030)
2.3 Global Anti-erectile Dysfunction (ED) Drugs Sales Estimates and Forecasts 2019-2030
2.4 Global Anti-erectile Dysfunction (ED) Drugs Sales by Region
2.4.1 Global Anti-erectile Dysfunction (ED) Drugs Sales by Region: 2019 VS 2023 VS 2030
2.4.2 Global Anti-erectile Dysfunction (ED) Drugs Sales by Region (2019-2024)
2.4.3 Global Anti-erectile Dysfunction (ED) Drugs Sales by Region (2025-2030)
2.4.4 Global Anti-erectile Dysfunction (ED) Drugs Sales 麻豆原创 Share by Region (2019-2030)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Anti-erectile Dysfunction (ED) Drugs Sales by Manufacturers
3.1.1 Global Anti-erectile Dysfunction (ED) Drugs Sales by Manufacturers (2019-2024)
3.1.2 Global Anti-erectile Dysfunction (ED) Drugs Sales 麻豆原创 Share by Manufacturers (2019-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Anti-erectile Dysfunction (ED) Drugs in 2023
3.2 Global Anti-erectile Dysfunction (ED) Drugs Revenue by Manufacturers
3.2.1 Global Anti-erectile Dysfunction (ED) Drugs Revenue by Manufacturers (2019-2024)
3.2.2 Global Anti-erectile Dysfunction (ED) Drugs Revenue 麻豆原创 Share by Manufacturers (2019-2024)
3.2.3 Global Top 10 and Top 5 Companies by Anti-erectile Dysfunction (ED) Drugs Revenue in 2023
3.3 Global Key Players of Anti-erectile Dysfunction (ED) Drugs, Industry Ranking, 2022 VS 2023 VS 2024
3.4 Global Anti-erectile Dysfunction (ED) Drugs Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers 麻豆原创 Concentration Ratio (CR5 and HHI)
3.5.2 Global Anti-erectile Dysfunction (ED) Drugs 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Anti-erectile Dysfunction (ED) Drugs, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Anti-erectile Dysfunction (ED) Drugs, Product Offered and Application
3.8 Global Key Manufacturers of Anti-erectile Dysfunction (ED) Drugs, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 麻豆原创 Size by Type
4.1 Global Anti-erectile Dysfunction (ED) Drugs Sales by Type
4.1.1 Global Anti-erectile Dysfunction (ED) Drugs Historical Sales by Type (2019-2024)
4.1.2 Global Anti-erectile Dysfunction (ED) Drugs Forecasted Sales by Type (2025-2030)
4.1.3 Global Anti-erectile Dysfunction (ED) Drugs Sales 麻豆原创 Share by Type (2019-2030)
4.2 Global Anti-erectile Dysfunction (ED) Drugs Revenue by Type
4.2.1 Global Anti-erectile Dysfunction (ED) Drugs Historical Revenue by Type (2019-2024)
4.2.2 Global Anti-erectile Dysfunction (ED) Drugs Forecasted Revenue by Type (2025-2030)
4.2.3 Global Anti-erectile Dysfunction (ED) Drugs Revenue 麻豆原创 Share by Type (2019-2030)
4.3 Global Anti-erectile Dysfunction (ED) Drugs Price by Type
4.3.1 Global Anti-erectile Dysfunction (ED) Drugs Price by Type (2019-2024)
4.3.2 Global Anti-erectile Dysfunction (ED) Drugs Price Forecast by Type (2025-2030)
5 麻豆原创 Size by Application
5.1 Global Anti-erectile Dysfunction (ED) Drugs Sales by Application
5.1.1 Global Anti-erectile Dysfunction (ED) Drugs Historical Sales by Application (2019-2024)
5.1.2 Global Anti-erectile Dysfunction (ED) Drugs Forecasted Sales by Application (2025-2030)
5.1.3 Global Anti-erectile Dysfunction (ED) Drugs Sales 麻豆原创 Share by Application (2019-2030)
5.2 Global Anti-erectile Dysfunction (ED) Drugs Revenue by Application
5.2.1 Global Anti-erectile Dysfunction (ED) Drugs Historical Revenue by Application (2019-2024)
5.2.2 Global Anti-erectile Dysfunction (ED) Drugs Forecasted Revenue by Application (2025-2030)
5.2.3 Global Anti-erectile Dysfunction (ED) Drugs Revenue 麻豆原创 Share by Application (2019-2030)
5.3 Global Anti-erectile Dysfunction (ED) Drugs Price by Application
5.3.1 Global Anti-erectile Dysfunction (ED) Drugs Price by Application (2019-2024)
5.3.2 Global Anti-erectile Dysfunction (ED) Drugs Price Forecast by Application (2025-2030)
6 US & Canada
6.1 US & Canada Anti-erectile Dysfunction (ED) Drugs 麻豆原创 Size by Type
6.1.1 US & Canada Anti-erectile Dysfunction (ED) Drugs Sales by Type (2019-2030)
6.1.2 US & Canada Anti-erectile Dysfunction (ED) Drugs Revenue by Type (2019-2030)
6.2 US & Canada Anti-erectile Dysfunction (ED) Drugs 麻豆原创 Size by Application
6.2.1 US & Canada Anti-erectile Dysfunction (ED) Drugs Sales by Application (2019-2030)
6.2.2 US & Canada Anti-erectile Dysfunction (ED) Drugs Revenue by Application (2019-2030)
6.3 US & Canada Anti-erectile Dysfunction (ED) Drugs 麻豆原创 Size by Country
6.3.1 US & Canada Anti-erectile Dysfunction (ED) Drugs Revenue by Country: 2019 VS 2023 VS 2030
6.3.2 US & Canada Anti-erectile Dysfunction (ED) Drugs Sales by Country (2019-2030)
6.3.3 US & Canada Anti-erectile Dysfunction (ED) Drugs Revenue by Country (2019-2030)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Anti-erectile Dysfunction (ED) Drugs 麻豆原创 Size by Type
7.1.1 Europe Anti-erectile Dysfunction (ED) Drugs Sales by Type (2019-2030)
7.1.2 Europe Anti-erectile Dysfunction (ED) Drugs Revenue by Type (2019-2030)
7.2 Europe Anti-erectile Dysfunction (ED) Drugs 麻豆原创 Size by Application
7.2.1 Europe Anti-erectile Dysfunction (ED) Drugs Sales by Application (2019-2030)
7.2.2 Europe Anti-erectile Dysfunction (ED) Drugs Revenue by Application (2019-2030)
7.3 Europe Anti-erectile Dysfunction (ED) Drugs 麻豆原创 Size by Country
7.3.1 Europe Anti-erectile Dysfunction (ED) Drugs Revenue by Country: 2019 VS 2023 VS 2030
7.3.2 Europe Anti-erectile Dysfunction (ED) Drugs Sales by Country (2019-2030)
7.3.3 Europe Anti-erectile Dysfunction (ED) Drugs Revenue by Country (2019-2030)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Anti-erectile Dysfunction (ED) Drugs 麻豆原创 Size
8.1.1 China Anti-erectile Dysfunction (ED) Drugs Sales (2019-2030)
8.1.2 China Anti-erectile Dysfunction (ED) Drugs Revenue (2019-2030)
8.2 China Anti-erectile Dysfunction (ED) Drugs 麻豆原创 Size by Application
8.2.1 China Anti-erectile Dysfunction (ED) Drugs Sales by Application (2019-2030)
8.2.2 China Anti-erectile Dysfunction (ED) Drugs Revenue by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Anti-erectile Dysfunction (ED) Drugs 麻豆原创 Size by Type
9.1.1 Asia Anti-erectile Dysfunction (ED) Drugs Sales by Type (2019-2030)
9.1.2 Asia Anti-erectile Dysfunction (ED) Drugs Revenue by Type (2019-2030)
9.2 Asia Anti-erectile Dysfunction (ED) Drugs 麻豆原创 Size by Application
9.2.1 Asia Anti-erectile Dysfunction (ED) Drugs Sales by Application (2019-2030)
9.2.2 Asia Anti-erectile Dysfunction (ED) Drugs Revenue by Application (2019-2030)
9.3 Asia Anti-erectile Dysfunction (ED) Drugs Sales by Region
9.3.1 Asia Anti-erectile Dysfunction (ED) Drugs Revenue by Region: 2019 VS 2023 VS 2030
9.3.2 Asia Anti-erectile Dysfunction (ED) Drugs Revenue by Region (2019-2030)
9.3.3 Asia Anti-erectile Dysfunction (ED) Drugs Sales by Region (2019-2030)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Anti-erectile Dysfunction (ED) Drugs 麻豆原创 Size by Type
10.1.1 Middle East, Africa and Latin America Anti-erectile Dysfunction (ED) Drugs Sales by Type (2019-2030)
10.1.2 Middle East, Africa and Latin America Anti-erectile Dysfunction (ED) Drugs Revenue by Type (2019-2030)
10.2 Middle East, Africa and Latin America Anti-erectile Dysfunction (ED) Drugs 麻豆原创 Size by Application
10.2.1 Middle East, Africa and Latin America Anti-erectile Dysfunction (ED) Drugs Sales by Application (2019-2030)
10.2.2 Middle East, Africa and Latin America Anti-erectile Dysfunction (ED) Drugs Revenue by Application (2019-2030)
10.3 Middle East, Africa and Latin America Anti-erectile Dysfunction (ED) Drugs Sales by Country
10.3.1 Middle East, Africa and Latin America Anti-erectile Dysfunction (ED) Drugs Revenue by Country: 2019 VS 2023 VS 2030
10.3.2 Middle East, Africa and Latin America Anti-erectile Dysfunction (ED) Drugs Revenue by Country (2019-2030)
10.3.3 Middle East, Africa and Latin America Anti-erectile Dysfunction (ED) Drugs Sales by Country (2019-2030)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Vivus, Inc.
11.1.1 Vivus, Inc. Company Information
11.1.2 Vivus, Inc. Overview
11.1.3 Vivus, Inc. Anti-erectile Dysfunction (ED) Drugs Sales, Price, Revenue and Gross Margin (2019-2024)
11.1.4 Vivus, Inc. Anti-erectile Dysfunction (ED) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Vivus, Inc. Recent Developments
11.2 Lilly ICOS LLC
11.2.1 Lilly ICOS LLC Company Information
11.2.2 Lilly ICOS LLC Overview
11.2.3 Lilly ICOS LLC Anti-erectile Dysfunction (ED) Drugs Sales, Price, Revenue and Gross Margin (2019-2024)
11.2.4 Lilly ICOS LLC Anti-erectile Dysfunction (ED) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Lilly ICOS LLC Recent Developments
11.3 Pfizer
11.3.1 Pfizer Company Information
11.3.2 Pfizer Overview
11.3.3 Pfizer Anti-erectile Dysfunction (ED) Drugs Sales, Price, Revenue and Gross Margin (2019-2024)
11.3.4 Pfizer Anti-erectile Dysfunction (ED) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Pfizer Recent Developments
11.4 Bayer
11.4.1 Bayer Company Information
11.4.2 Bayer Overview
11.4.3 Bayer Anti-erectile Dysfunction (ED) Drugs Sales, Price, Revenue and Gross Margin (2019-2024)
11.4.4 Bayer Anti-erectile Dysfunction (ED) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Bayer Recent Developments
11.5 Hims
11.5.1 Hims Company Information
11.5.2 Hims Overview
11.5.3 Hims Anti-erectile Dysfunction (ED) Drugs Sales, Price, Revenue and Gross Margin (2019-2024)
11.5.4 Hims Anti-erectile Dysfunction (ED) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Hims Recent Developments
11.6 Menarini Group
11.6.1 Menarini Group Company Information
11.6.2 Menarini Group Overview
11.6.3 Menarini Group Anti-erectile Dysfunction (ED) Drugs Sales, Price, Revenue and Gross Margin (2019-2024)
11.6.4 Menarini Group Anti-erectile Dysfunction (ED) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Menarini Group Recent Developments
11.7 Lupin
11.7.1 Lupin Company Information
11.7.2 Lupin Overview
11.7.3 Lupin Anti-erectile Dysfunction (ED) Drugs Sales, Price, Revenue and Gross Margin (2019-2024)
11.7.4 Lupin Anti-erectile Dysfunction (ED) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Lupin Recent Developments
11.8 Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
11.8.1 Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd Company Information
11.8.2 Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd Overview
11.8.3 Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd Anti-erectile Dysfunction (ED) Drugs Sales, Price, Revenue and Gross Margin (2019-2024)
11.8.4 Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd Anti-erectile Dysfunction (ED) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd Recent Developments
11.9 General Factory
11.9.1 General Factory Company Information
11.9.2 General Factory Overview
11.9.3 General Factory Anti-erectile Dysfunction (ED) Drugs Sales, Price, Revenue and Gross Margin (2019-2024)
11.9.4 General Factory Anti-erectile Dysfunction (ED) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 General Factory Recent Developments
11.10 CSBio
11.10.1 CSBio Company Information
11.10.2 CSBio Overview
11.10.3 CSBio Anti-erectile Dysfunction (ED) Drugs Sales, Price, Revenue and Gross Margin (2019-2024)
11.10.4 CSBio Anti-erectile Dysfunction (ED) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 CSBio Recent Developments
11.11 Dong-A ST
11.11.1 Dong-A ST Company Information
11.11.2 Dong-A ST Overview
11.11.3 Dong-A ST Anti-erectile Dysfunction (ED) Drugs Sales, Price, Revenue and Gross Margin (2019-2024)
11.11.4 Dong-A ST Anti-erectile Dysfunction (ED) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Dong-A ST Recent Developments
11.12 Metuchen Pharma
11.12.1 Metuchen Pharma Company Information
11.12.2 Metuchen Pharma Overview
11.12.3 Metuchen Pharma Anti-erectile Dysfunction (ED) Drugs Sales, Price, Revenue and Gross Margin (2019-2024)
11.12.4 Metuchen Pharma Anti-erectile Dysfunction (ED) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Metuchen Pharma Recent Developments
11.13 Seoul Pharma
11.13.1 Seoul Pharma Company Information
11.13.2 Seoul Pharma Overview
11.13.3 Seoul Pharma Anti-erectile Dysfunction (ED) Drugs Sales, Price, Revenue and Gross Margin (2019-2024)
11.13.4 Seoul Pharma Anti-erectile Dysfunction (ED) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Seoul Pharma Recent Developments
11.14 Teva Pharma
11.14.1 Teva Pharma Company Information
11.14.2 Teva Pharma Overview
11.14.3 Teva Pharma Anti-erectile Dysfunction (ED) Drugs Sales, Price, Revenue and Gross Margin (2019-2024)
11.14.4 Teva Pharma Anti-erectile Dysfunction (ED) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Teva Pharma Recent Developments
11.15 S.K. Chemicals
11.15.1 S.K. Chemicals Company Information
11.15.2 S.K. Chemicals Overview
11.15.3 S.K. Chemicals Anti-erectile Dysfunction (ED) Drugs Sales, Price, Revenue and Gross Margin (2019-2024)
11.15.4 S.K. Chemicals Anti-erectile Dysfunction (ED) Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 S.K. Chemicals Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Anti-erectile Dysfunction (ED) Drugs Industry Chain Analysis
12.2 Anti-erectile Dysfunction (ED) Drugs Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Anti-erectile Dysfunction (ED) Drugs Production Mode & Process
12.4 Anti-erectile Dysfunction (ED) Drugs Sales and 麻豆原创ing
12.4.1 Anti-erectile Dysfunction (ED) Drugs Sales Channels
12.4.2 Anti-erectile Dysfunction (ED) Drugs Distributors
12.5 Anti-erectile Dysfunction (ED) Drugs Customers
13 麻豆原创 Dynamics
13.1 Anti-erectile Dysfunction (ED) Drugs Industry Trends
13.2 Anti-erectile Dysfunction (ED) Drugs 麻豆原创 Drivers
13.3 Anti-erectile Dysfunction (ED) Drugs 麻豆原创 Challenges
13.4 Anti-erectile Dysfunction (ED) Drugs 麻豆原创 Restraints
14 Key Findings in The Global Anti-erectile Dysfunction (ED) Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
Vivus, Inc.
Lilly ICOS LLC
Pfizer
Bayer
Hims
Menarini Group
Lupin
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
General Factory
CSBio
Dong-A ST
Metuchen Pharma
Seoul Pharma
Teva Pharma
S.K. Chemicals
听
听
*If Applicable.